Patents Assigned to Genentech
  • Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
    Publication number: 20140079689
    Abstract: Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
    Type: Application
    Filed: August 2, 2013
    Publication date: March 20, 2014
    Applicant: GENENTECH, INC.
    Inventors: MICHAEL J. ELLIOTT, JUSTIN SCHEER
  • Polypeptide variants with altered effector function
    Patent number: 8674083
    Abstract: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: March 18, 2014
    Assignee: Genentech, Inc.
    Inventor: Leonard Presta
  • 8-fluorophthalazin-1(2H)-one compounds
    Patent number: 8669251
    Abstract: 8-Fluorophthalazin-1(2h)-one compounds of Formula II where one or two of X1, X2, and X3 are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula II for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: March 11, 2014
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • DIOXINO- AND OXAZIN-[2,3-D]PYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20140065136
    Abstract: Dioxino- and oxazin-[2,3-d]pyrimidine PI3K inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions.
    Type: Application
    Filed: August 29, 2013
    Publication date: March 6, 2014
    Applicant: Genentech, Inc.
    Inventors: Robert Andrew Heald, Neville James McLean
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
    Publication number: 20140065135
    Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: July 30, 2013
    Publication date: March 6, 2014
    Applicant: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20140066453
    Abstract: Compounds having the formula I wherein R2, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Application
    Filed: August 27, 2013
    Publication date: March 6, 2014
    Applicants: Genentech, Inc., Array BioPharma Inc.
    Inventors: Jim Blake, Huifen Chen, Mark Chicarelli, John Gaudino, Lewis Gazzard, Sam Kintz, Pete Mohr, Kirk Robarge, Jacob Schwarz, Aihe Zhou
  • HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF
    Publication number: 20140065137
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: September 20, 2013
    Publication date: March 6, 2014
    Applicant: GENENTECH, INC.
    Inventors: Arthur Huang, Robert Kelley, Henry Lowman, Menno Van Lookeren Campagne, Charles Winter
  • COMBINATION THERAPY
    Publication number: 20140065160
    Abstract: The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various diseases or disorders characterized by cells expressing CD40 with a combination of an agent causes the depletion of cells expressing CD40 and a second agent which causes the depletion of cells expressing the CD20 membrane antigen. Pharmaceutical compositions and articles of manufacture such as kits comprising the agents and combinations thereof are also provided.
    Type: Application
    Filed: November 5, 2013
    Publication date: March 6, 2014
    Applicant: Genentech, Inc.
    Inventor: Igbal GREWAL
  • Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
    Patent number: 8663643
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: March 4, 2014
    Assignee: Genentech, Inc.
    Inventors: Leanne Berry, Gail Lewis Phillips, Mark X. Sliwkowski
  • Hepatocyte Growth Factor Receptor Antagonists and Uses Thereof
    Publication number: 20140056921
    Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
    Type: Application
    Filed: June 6, 2013
    Publication date: February 27, 2014
    Applicant: Genentech, Inc.
    Inventors: Ralph H. Schwall, Kelly H. Tabor
  • SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
    Publication number: 20140056884
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Application
    Filed: October 24, 2013
    Publication date: February 27, 2014
    Applicants: Genentech, Inc., Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc.
    Inventors: Xiaoping Zhang, Kimio Terao, Angelika M. Jahreis
  • COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES
    Publication number: 20140056889
    Abstract: The invention provides methods and compositions for treating various autoimmune diseases (such as systemic lupus erythematousu) with an interferon inhibitor (such as an anti-intereron-alpha monoclonal antibody). More specifically, the invention provides a method of diagnosing, monitoring and adjusting the treatment of such a patient by way of an interferon signature metric (interferon response gene measurement value), a certain anti-dsDNA antibody titre or being ENA? (levels of extractable nuclear antigens lower than a healthy level). Furthermore, the invention provides articles of manufacture associated with such a diagnosis.
    Type: Application
    Filed: April 26, 2012
    Publication date: February 27, 2014
    Applicant: Genentech, Inc.
    Inventors: Alyssa M. Morimoto, Jacqueline McBride, Richard Boismenu, Romeo Maciuca, William D. Kennedy, Michael J. Townsend, Jorn Drappa
  • BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20140058098
    Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: October 7, 2013
    Publication date: February 27, 2014
    Applicant: Genentech, Inc.
    Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
  • METHOD TO IDENTIFY A PATEINT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY
    Publication number: 20140056874
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 27, 2014
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: Herbert Andres, Sanne Lysbet De Haas, Rebecca Elliott, Johann Karl, Yu-Ju Gloria Meng, Gregory D. Plowman, Stefan Scherer, Norbert Wild
  • ANTI-HER ANTIBODIES
    Publication number: 20140056899
    Abstract: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.
    Type: Application
    Filed: October 29, 2013
    Publication date: February 27, 2014
    Applicant: GENENTECH, INC.
    Inventors: Germaine Fuh, Lauric Haber, Gabriele Schaefer, Mark X. Sliwkowski
  • METHOD TO IDENTIFY A PATEINT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY
    Publication number: 20140056875
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 27, 2014
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: Herbert Andres, Sanne Lysbet De Haas, Rebecca Elliott, Johann Karl, Yu-Ju Gloria Meng, Gregory D. Plowman, Stefan Scherer, Norbert Wild
  • HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME
    Publication number: 20140051120
    Abstract: The present invention concerns antibodies to EGFL7 and the uses of same.
    Type: Application
    Filed: November 2, 2012
    Publication date: February 20, 2014
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
    Patent number: 8652474
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: February 18, 2014
    Assignee: Genentech, Inc.
    Inventors: Reed J. Harris, Paul A. Motchnik
  • Antibody-drug conjugates and methods
    Patent number: 8652479
    Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: February 18, 2014
    Assignee: Genentech, Inc.
    Inventors: Allen J. Ebens, Jr., Frederic S. Jacobson, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Pyrazolopyridine PI3K inhibitor compounds and methods of use
    Patent number: 8653098
    Abstract: Compounds of Formula (I), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer or inflammation mediated by lipid kinases. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: February 18, 2014
    Assignee: Genentech, Inc.
    Inventors: Jennafer Dotson, Timothy Heffron, Alan G. Olivero, Daniel P. Sutherlin, Steven Staben, Shumei Wang, Bing-Yan Zhu, Irina S. Chuckowree, Adrian J. Folkes, Nan Chi Wan